Studies | Follow-up periods | Clinical outcomes |
---|---|---|
Liu et al | 36 ± 12 months | Cardiac death, AMI, TLR, MACE |
Claessen et al | 5Â years | All-cause mortality, MI, TVR, CABG, MACE |
Sohrabi et al | 12Â months | Cardiac death, Non-cardiac death, MI, TVR, MACE |
Ruiz-Garcia | 12Â months | Death, TVR, AMI, stent thrombosis, stroke, MACE |
Rha et al | 12Â months | Total death, cardiac death, MI, TLR, TVR, TLR-MACE, TVR-MACEs, Total MACE |
Yang et al | 13.5 ± 4.1 months | All-cause death, cardiac death, MI, stroke, repeat revascularization, MACCE |
Sanguineti et al | 4.2 (2.5–6.6) years | All-cause mortality, cardiac death, TLR, Total TVR, CABG, MI, MACE |
Tsai et al | 5 (1–10) years | All-cause mortality, cardiovascular mortality, MI, MACE |
Guo et al | 2.6 (1.2–4.7) years | Cardiac mortality, MI, TVR, and MACE |
Yan et al | 42(24–78.25) months | All-cause death, cardiac death, MI, repeat revascularization, TVR |
Flores-Umanzor et al | 4.03 (2.6–4.8) years | All-cause death, cardiac death, AMI, PCI-of non-CTO vessel, heart failure hospitalization |